These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31456453)

  • 21. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study.
    Guvenmez O; Cubuk M; Gunes S
    J Popul Ther Clin Pharmacol; 2020 May; 27(2):e45-e50. PubMed ID: 32379404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
    Faber A; van Agthoven M; Kalverdijk LJ; Tobi H; de Jong-van den Berg LT; Annemans L; Postma MJ
    CNS Drugs; 2008; 22(2):157-70. PubMed ID: 18193926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QTc prolongation after ADHD medication.
    Snircova E; Marcincakova Husarova V; Ondrejka I; Hrtanek I; Farsky I; Nosalova G
    Neuro Endocrinol Lett; 2018 Feb; 38(8):549-554. PubMed ID: 29504733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
    Husarova V; Bittsansky M; Ondrejka I; Dobrota D
    Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. InforMatrix for attention deficit hyperactivity disorder.
    Janknegt R; Faber A; Rodrigues Pereira R; Kalverdijk LJ
    Expert Opin Pharmacother; 2009 Apr; 10(5):755-72. PubMed ID: 19351226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
    Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
    Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
    Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
    J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
    Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL; Chia S; Shang CY; Gau SS
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second opinions improve ADHD prescribing in a medicaid-insured community population.
    Thompson JN; Varley CK; McClellan J; Hilt R; Lee T; Kwan AC; Lee T; Trupin E
    J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):740-748. PubMed ID: 19465882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.